Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9590989 | PMC |
Publication Analysis
Top Keywords
Similar Publications
From Outbreaks to Artificial Intelligence: A Comprehensive Review of Monkeypox Virus Epidemiology, Diagnosis, Treatment, Vaccination, and Deep Learning Applications.
J Trop Med
December 2024
Department of Infectious Disease, Faculty of Medicine, Aja University of Medical Sciences, Tehran, Iran.
After the global impact of the COVID-19 pandemic, concerns over virus transmission have risen. A state of health emergency was declared in 2022 due to Clade 2 of the monkeypox (MPOX) virus. In August 2024, another emergency was declared by the World Health Organization (WHO) because of the widespread Clade 1b, which caused a more severe and lethal disease.
View Article and Find Full Text PDFThe historical evolution of smallpox treatment in Japan visualised through Japanese artwork and woodblock prints.
J R Coll Physicians Edinb
December 2024
Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Art reveals core human emotions during catastrophes like epidemics, allowing people to narrate their coping stories. This review examines smallpox's historical evolution and treatment in Japan, integrating visual art with medical history. It provides chronological insights from smallpox's arrival and traditional remedies to the era of vaccination and public health measures leading to eventual eradication.
View Article and Find Full Text PDFEffectiveness of Tecovirimat in Mpox Cases: A Systematic Review of Current Evidence.
J Med Virol
December 2024
SR Sanjeevani Hospital, Kalyanpur, Siraha, Nepal.
Mpox, formerly known as monkeypox, has re-emerged as a significant global health concern, particularly during the widespread outbreak of 2022. As an orthopoxvirus related to the eradicated smallpox virus, mpox has been primarily managed with smallpox vaccines and treatments, including the antiviral agent Tecovirimat. This systematic review aims to evaluate the effectiveness and safety of Tecovirimat in treating mpox, focusing on its use during the 2022 outbreak, especially among high-risk populations, including men who have sex with men and people living with HIV.
View Article and Find Full Text PDFMonkeypox (Mpox): Diagnosis and Emerging Challenges.
Yale J Biol Med
December 2024
Multidisciplinary Research Unit, Maulana Azad Medical College and Associated Hospital, New Delhi, India.
Monkeypox (Mpox) has once again been designated a Public Health Emergency of International Concern (PHEIC) as of August, 2024. The severity of the disease is underscored by its significant mortality rate, and unfortunately, there are no targeted therapeutics currently available for this viral infection. Management relies on preventive measures and the use of existing smallpox vaccines due to their genetic similarity to the Mpox virus.
View Article and Find Full Text PDFStrengthening Africa's response to Mpox (monkeypox): insights from historical outbreaks and the present global spread.
Sci One Health
October 2024
Endoscopy Unit, Glenfield Hospital, University Hospitals of Leicester, NHS Trust, Leicester, United Kingdom.
Mpox, formerly known as Monkeypox, is a viral zoonotic disease endemic to Central and West Africa that has posed significant public health challenges since its identification in 1970. Despite decades of experience in managing outbreaks, the 2022-2024 Mpox outbreaks exposed substantial gaps in global preparedness and response, leading the World Health Organization (WHO) to declare a Public Health Emergency of International Concern (PHEIC) in 2022. The resurgence of cases in Europe in 2022 and the more recent emergence of the virulent clade Ⅰb in the Democratic Republic of the Congo (DRC) in 2024 have highlighted a critical need for improved proactive and response strategies to curb the epidemic.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!